THE SHARE: Change: +0.00 SEK (+0.83%) / Price: 0.12 SEK / Mar 16, 2026, 11:27 am (CET)
  • Home
  • About
    • Introduction
    • Board of Directors
    • Management Team
    • Medical Advisors
    • Corporate Governance
    • Career
  • Technology
    • Physiological Targeting
    • Functional Nanoparticles
    • Publications
    • Patent
  • Portfolio
    • Pipeline
    • SpagoPix
    • Tumorad
  • Investor Relations
    • The Share
    • Analyst Coverage
    • Owners
    • Financial Reports
    • Financial Calendar
    • Equity research
    • Shareholder’s Personal Data
    • Share Issue
  • Media
    • Spago Nanomedical in media
    • Press Releases
    • Subscribe
    • Presentations
    • Events
    • Image Bank
  • Contact
    • Contact us

  • 8 Dec, 2011
    Incubator company receives 3.6 MSEK
  • 16 Nov, 2011
    VINNOVA financing to SPAGO Imaging
  • 26 Oct, 2011
    Gadolinium-free MRI contrast agent
  • 20 Oct, 2011
    SPAGO Recruits a Study Coordination Director
  • 20 Dec, 2010
    Product patent in South Africa
  • 8 Sep, 2010
    Board promotion
  • 8 Sep, 2010
    Åsa Sjöholm Timén recruited to lead SPAGO Imaging’s Business Development activities
  • 28 Jun, 2010
    Sensational Enhancement
  • 29 Mar, 2010
    SPAGO i Veckans Affärer
  • 12 Mar, 2010
    New recruit to the Board of Directors
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • Previous
  • Next
Back

About Spago Nanomedical

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of life-threatening and debilitating diseases.

Address

Spago Nanomedical AB
Scheelevägen 22
SE-223 63 Lund
Sweden

Contact

Phone: +46 46 811 88
LinkedIn

Member of:

Copyright © 2026 Spago Nanomedical AB. All Rights Reserved.
Design by Clavis Communications